Abstract
Background Antibiotic resistance has become a serious global health threat. Wastewater treatment plants (WWTPs) may become unintentional collection points for bacteria resistant to antimicrobials. Little is known about the transmission of antibiotic resistance from wastewater treatment plants to humans, most importantly to WWTP workers and residents living in the vicinity. We aim to deliver precise information about the methods used in the AWARE (Antibiotic Resistance in Wastewater: Transmission Risks for Employees and Residents around Waste Water Treatment Plants) study.
Methods/Design Within the AWARE study, we gather data on the prevalence of two antibiotic resistance phenotypes, ESBL-producing E.coli (ESBL-EC) and carbapenemase-producing Enterobacteriaceae (CPE) as well as on their corresponding antibiotic resistance genes (ARGs) isolated from air, water, and sewage samples taken from inside and outside of different WWTPs in Germany, Netherlands and Romania. Additionally, we analyse stool samples of WWTP workers, nearby residents and members of a comparison group living ≥1,000 m away from the closest WWTP.
Discussion The study results will enable the assessment of the potential health impact of exposure to ESBL-EC, CPE and ARGs in and around WWTPs. Quantifying the contribution of different wastewater treatment processes to the ESBL-EC, CPE and ARGs removal efficiency will provide us with evidence-based support for possible mitigation strategies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This publication describes the methods of a cross-sectional study for which a trial ID is not necessary.
Funding Statement
AWARE (Antibiotic Resistance in Wastewater: Transmission Risks for Employees and Residents around Wastewater Treatment Plants) is supported by the European Commission (JPI-EC-AMR ERA-Net Cofund grant no 681055).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was received by the responsible ethics committees of the participating study centres in DE (Committee: Ethikkommission bei der medizinsichen Fakultaet der LMU Muenchen, number of approval: 17-734) and RO (Committee: Comisia de Etică a Cercetării, number of approval: 164/05.12.2017). In NL this research is exempted for ethical approval under the Dutch Medical Research Involving Human Subjects Act (WMO; Committee: Medisch Ethische Toetsingscommissie, number of confirmation: 19-001/C).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This publication describes the methods of a cross-sectional study. Since the study is not finalized yet, data sets are not finalized and are therefore are not available yet.
